Journal Article

Understanding the Role of HIV Load in Determining Weight Change in the Era of Highly Active Antiretroviral Therapy

D. Mkaya Mwamburi, Ira B. Wilson, Denise L. Jacobson, Donna Spiegelman, Sherwood L. Gorbach, Tamsin A. Knox and Christine A. Wanke

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 40, issue 1, pages 167-173
Published in print January 2005 | ISSN: 1058-4838
Published online January 2005 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/426591
Understanding the Role of HIV Load in Determining Weight Change in the Era of Highly Active Antiretroviral Therapy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Background. In this prospective cohort study, we determined the relationship between human immunodeficiency virus (HIV) RNA load and body weight in patients with HIV infection.

Methods. Repeated-measures analysis was restricted to patients with ⩾2 study visits, 4–9-month intervals between study visits, and complete data on virus load, resting energy expenditure (REE), and highly active antiretroviral therapy (HAART). The outcome was change in body weight across study intervals. The main predictor was virus load. Separate analyses were performed for weight change in patients receiving and patients not receiving HAART.

Results. The eligible sample consisted of 318 participants associated with 1886 study intervals. Sixty-one patients (19%) were women, and 173 (54%) were undergoing HAART at the time of enrollment. There was a significant interaction (P = .01) between virus load and HAART use. In the absence of HAART, each log10 increase in virus load was associated with a 0.92-kg decrease in body weight (P = .003), but during HAART, virus load was not significantly associated with weight change. During HAART, a CD4+ cell count decrease of 100 cells/mm3, rather than a change in the virus load, was associated with a 0.35-kg decrease in body weight (P < .001). REE was independently associated with weight change in both models (P < .001).

Conclusions. Patients with HIV infection who are losing weight and are not taking HAART should be considered for HAART. Patients who are already receiving HAART and have unsuppressed virus loads may benefit virologically from an intensified regimen, because such a regimen may lead to complete suppression if there is an accompanying increase in CD4+ cell counts. Further research is needed to understand the strong independent effect of changes in REE among patients receiving and patients not receiving HAART.

Journal Article.  4140 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.